Trials
3 active
3 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.”In the company’s words, NCT06786234 on ClinicalTrials.gov
- Main trialPhase 2
- “The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are: * Does STP938 control platelet counts * Does STP938 control platelet counts without inducing unwanted side effects Participants will: * Take STP938 every day for up to 12 months. * Visit the clinic once every week for the first month, then every 2 weeks for checkups…”In the company’s words, NCT06786234 on ClinicalTrials.gov
Other drugs for Essential Thrombocythaemia
- BomedemstatMerck & Co. · Phase 3
- Pegylated-Proline-interferon alpha-2bAOP Orphan Pharmaceuticals AG · Phase 3
- INCA033989Incyte Corporation · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 2
- JBI-802Jubilant Therapeutics Inc. · Phase 1/2
Coming up3
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2028 | A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial | |
| Phase 1/2Recruiting | Dec 2026 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | |
| Phase 1Recruiting | Dec 2026 | Study of STP938 (Dencatistat) in Advanced Solid Tumours |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026